Biopharma | 13 August 2026
Stempeutics secures US patent for stem cell-based osteoarthritis treatment
USPTO patent covers ultrasound-guided administration of Stempeucel-OA for Grade II and III knee osteoarthritis
USPTO patent covers ultrasound-guided administration of Stempeucel-OA for Grade II and III knee osteoarthritis
Under the revised plan, the facility will combine biologics and biosimilar manufacturing capabilities with its existing small-molecule oncology line
Zydus Lifesciences subsidiary Sentynl Therapeutics will have an exclusive option to acquire a licence to commercialise the drug in the United States, while Mereo BioPharma will retain commercial rights in the rest of the world
The acquisition provides Amneal access to the global biosimilars opportunity, with more than USD 300 billion in projected biologics loss of exclusivity over the next decade
The expansion will make the Singapore facility the first BioReliance site in Asia Pacific to offer both Cell Line Characterization services and GMP next-generation sequencing (NGS) capabilities
The new center is expected to become operational in 2027 and will be part of Amgen’s global network of seven research laboratories
OPUVIZ contains aflibercept, a vascular endothelial growth factor (VEGF) inhibitor and recombinant fusion protein designed to block abnormal blood vessel growth and leakage in the eye
The agreement grants worldwide rights to the partner for the development and commercialisation of a recombinant human hyaluronidase developed using Alteogen's Hybrozyme platform
Profit after tax (PAT) rose 36.2% to Rs. 292.5 crore, while PAT margin expanded 110 basis points to 11.3%
The company reported EBITDA of Rs 902 crore, while continued balance sheet optimisation helped reduce interest costs by 23% year-on-year, supporting overall profitability
The vaccine has undergone extensive laboratory evaluation, including tests for sterility, purity, safety, genetic stability, immunogenicity, protective efficacy and virulence reversion
FDA-approved aflibercept biosimilar strengthens Biocon's ophthalmology portfolio and expands patient access to affordable vision care
Published research suggests six-in-one vaccine may reduce injections, ease health worker workload, lower cold-chain needs, and become cost-effective with affordable pricing
The collaboration will initially focus on client programs involving complex biologics, including bispecific and multispecific antibodies, fusion proteins and high-concentration formulations
LEQEMBI is indicated for patients with Mild Cognitive Impairment (MCI) and mild dementia due to early Alzheimer's disease
Company’s oncology business also recorded significant growth, led by Jemperli (dostarlimab) and Zejula (niraparib), both launched in August last year
Consolidated revenue from operations grows to Rs. 257.5 crore, driven by strong business momentum and improved profitability
The platform is designed to support efficient protein maturation and proteolytic processing while delivering enhanced biologic activity and higher yields for complex coagulation factors
Kiran Mazumdar-Shaw assumes Executive Chairperson role as company navigates biologics headwinds
During the two-month residential program, scholars will work on research spanning artificial intelligence, machine learning, drug discovery, healthcare, cheminformatics, genomics, and related fields
Subscribe To Our Newsletter & Stay Updated
